Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yves, Gourmelin"'
Autor:
Theodore E. Spiro, Jean Luc Martinoli, Genevieve Contant, Elisabeth Perzborn, Gabriele Rohde, Meyer Michel Samama, Céline Guinet, Yves Gourmelin, Léna Le Flem
Publikováno v:
Thrombosis Journal
Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of which greatly decreases thrombin generation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbbb14c1e3b8e5f30bcbf7e92ab2ae69
https://pubmed.ncbi.nlm.nih.gov/23822763
https://pubmed.ncbi.nlm.nih.gov/23822763
Autor:
Meyer Michel, Samama, Genevieve, Contant, Theodore E, Spiro, Elisabeth, Perzborn, Lena Le, Flem, Céline, Guinet, Yves, Gourmelin, Jean Luc, Martinoli, W, Wijns
Publikováno v:
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 18(2)
This study evaluated the prothrombin time (PT) assay for the measurement of plasma concentrations of rivaroxaban using calibrators and controls. The intra- and interlaboratory precision of the measurement was investigated in a field trial involving 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46dadd9fd84e33fa5e5ddc383b2ba2ff
https://pubmed.ncbi.nlm.nih.gov/22387577
https://pubmed.ncbi.nlm.nih.gov/22387577
Autor:
M.M. Samama, Gabriele Rohde, Theodore E. Spiro, Yves Gourmelin, Genevieve Contant, Jean-Luc Martinoli, Elisabeth Perzborn, Céline Guinet, L. Le Flem
Publikováno v:
European Journal of Hospital Pharmacy. 19:236.3-237
Background Rivaroxaban is an oral, direct Factor Xa inhibitor approved for clinical use for the prevention and treatment of thromboembolic disorders across several indications. Routine coagulation monitoring is not required, but a quantitative determ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fdecb5f9a25f4c43dcddb7ae6400ecb
https://doi.org/10.1136/ejhpharm-2012-000074.398
https://doi.org/10.1136/ejhpharm-2012-000074.398
Autor:
M.M. Samama, Genevieve Contant, Yves Gourmelin, Elisabeth Perzborn, Céline Guinet, Theodore E. Spiro, Jean-Luc Martinoli, L. Le Flem
Publikováno v:
European Journal of Hospital Pharmacy. 19:236.1-236
Background Rivaroxaban is widely used in clinical practice. Although routine coagulation monitoring is not required, quantitative determination of rivaroxaban might be valuable in certain clinical circumstances. Variation in response sensitivity of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd655c809697b856a9dc38816f8de2ee
https://doi.org/10.1136/ejhpharm-2012-000074.396
https://doi.org/10.1136/ejhpharm-2012-000074.396
Autor:
Léna Le Flem, Jean Luc Martinoli, Yves Gourmelin, Meyer Michel Samama, Elisabeth Perzborn, Céline Guinet, Genevieve Contant, Theodore E. Spiro
Publikováno v:
Blood. 116:3330-3330
Abstract 3330 Background: Rivaroxaban is an oral, direct Factor Xa inhibitor in an advanced stage of clinical development for the prevention and treatment of thromboembolic disorders. It inhibits Factor Xa activity without requiring cofactors (such a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40a9b0a5e2633ea47f7288365b95aa62
https://doi.org/10.1182/blood.v116.21.3330.3330
https://doi.org/10.1182/blood.v116.21.3330.3330